Low dose precision formulation of pirimid and short-term dose regulation of active keratinase

摘要

Are revealed and described Pharmaceutical formulations and Methods for providing topical or transdermal 1 - isobutyl - 1H imidazo [4,5-c] quinolin-1 - 4 - Amine (aka, also known as 1 - (2-methylpropyl) - 1H imidazo [4,5-c] quinolin-1 - 4 - amino, aka imiquimodTherapies to treat Actinic keratosis with Shorter duration to the currently prescribed for Aldara 5% imiquimod Cream Commercially available, as currently approved by the food and Drug Administration of the United States of America (FDA).More specifically, Imiquimod formulations are revealed and described in less Concentrated Dose to provide an effective Dose to treat Actinic keratosis with an acceptable Safety Profile.But with a dosing regimen that is shorter and more suitable for use by patients the dose regimen currently approved by the FDA for Aldara 5% imiquimod Cream.